BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 21556025)

  • 1. Bone metastasis in prostate cancer: emerging therapeutic strategies.
    Sturge J; Caley MP; Waxman J
    Nat Rev Clin Oncol; 2011 Jun; 8(6):357-68. PubMed ID: 21556025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of osteoclastic activity in prostate cancer skeletal metastases.
    Keller ET
    Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
    Futakuchi M; Fukamachi K; Suzui M
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.
    Araujo A; Cook LM; Lynch CC; Basanta D
    Cancer Res; 2014 May; 74(9):2391-401. PubMed ID: 24788098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer].
    Lebret T; Méjean A; Houédé N
    Prog Urol; 2011 May; 21(5):301-7. PubMed ID: 21514531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting bone physiology for the treatment of metastatic prostate cancer.
    Autio KA; Morris MJ
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
    Seegenschmiedt MH; Oppenkowski R
    Praxis (Bern 1994); 2001 Sep; 90(38):1645-52. PubMed ID: 11675918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
    Saad F; Markus R; Goessl C
    BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical approaches to osseous metastases in prostate cancer.
    Morris MJ; Scher HI
    Oncologist; 2003; 8(2):161-73. PubMed ID: 12697941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.
    Terpos E; Confavreux CB; Clézardin P
    Bonekey Rep; 2015; 4():744. PubMed ID: 26512321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary therapeutic approaches targeting bone complications in prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Clin Genitourin Cancer; 2010 Dec; 8(1):29-36. PubMed ID: 21208853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and prevention of bone complications from prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.
    Chen PC; Cheng HC; Tang CH
    Carcinogenesis; 2013 Jul; 34(7):1669-79. PubMed ID: 23536580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.